Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed)

The Kidney Precision Medicine Project Tissue Interrogation Sites funding opportunity is issued by the National Institutes of Health within the U.S. Department of Health and Human Services, specifically through the National Institute of Diabetes and Digestive and Kidney Diseases. This initiative is part of a broader federal effort to advance biomedical research and improve clinical outcomes through precision medicine. The program focuses on generating deeper biological insights into kidney disease by leveraging advanced research infrastructure and collaborative scientific networks. The primary objective of this funding opportunity is to support Tissue Interrogation Sites that will analyze human kidney biopsy samples using highly integrated, multi-modal analytical approaches. These sites are expected to contribute to the identification and characterization of disease pathways and patient subgroups, thereby enabling the development of targeted and more effective clinical interventions. The program emphasizes collaboration across institutions and mandates participation in shared scientific discovery processes, with a strong commitment to open science principles and data sharing. Funding under this opportunity will be provided through a cooperative agreement mechanism, indicating substantial involvement from the funding agency in project oversight and coordination. The total estimated program funding is six million dollars, with approximately two awards anticipated. Each award may provide up to one million five hundred thousand dollars. Funds are intended to support research activities, including laboratory analysis, data integration, and collaborative efforts aligned with the Kidney Precision Medicine Project objectives. There is no cost sharing or matching requirement associated with this funding. Eligibility for this opportunity is broad and includes a wide range of domestic entities such as state and local governments, institutions of higher education, nonprofit organizations, for-profit entities, small businesses, and tribal governments and organizations. However, foreign organizations and non-U.S. components of U.S. organizations are explicitly excluded. Applicants are advised to consult the full Notice of Funding Opportunity for detailed eligibility criteria and any additional restrictions or requirements. Applications must be submitted electronically through the appropriate federal systems, typically involving registration with Grants.gov and related platforms. While the synopsis does not detail all application components, standard NIH submissions generally require a comprehensive research plan, budget justification, biosketches, and institutional documentation. The evaluation process will likely assess scientific merit, innovation, feasibility, and alignment with program goals, consistent with NIH review criteria. The application window opened on June 3, 2026, and closes on July 10, 2026. This represents a single-cycle funding opportunity with no indication of recurring availability. Applicants should ensure timely submission by the stated deadline, as late applications are typically not accepted. For questions or assistance, applicants may contact the Division of Kidney, Urologic, and Hematologic Diseases via the provided email address. Award notifications and project start dates are not specified in the synopsis but generally follow standard NIH timelines after peer review and administrative processing.